VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain

Emerging Infectious Diseases

Volumn 18, Issue 8, 2012, Pages 1235-1241

  Viedma, Esther ^a   Juan, Carlos ^b   Villa, Jennifer ^a   Barrado, Laura ^a   Angeles Orellana M ^a   Sanz, Francisca ^a   Otero, Joaquín R ^a   Oliver, Antonio ^b   Chaves, Fernando ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG; VIM 2 PROTEIN;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONE; FEMALE; GENOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOLECULAR TYPING; MULTILOCUS SEQUENCE TYPING; POLYMERASE CHAIN REACTION; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PULSED FIELD GEL ELECTROPHORESIS; RETROSPECTIVE STUDY; SPAIN;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; BETA-LACTAMASES; CROSS INFECTION; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEQUENCE ANALYSIS, DNA; SPAIN;

EID: 84864487092     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1808.111234     Document Type: Article

References (37)

1. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50:43-8. http://dx.doi.org/10.1128/AAC.50.1.43-48.2006
2. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34:634-40. http://dx.doi.org/10.1086/338782
3. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev. 2007;20:440-58. http://dx.doi.org/10.1128/CMR.00001-07
4. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis. 2011;11:381-93. http://dx.doi.org/10.1016/S1473-3099(11)70056-1
5. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18:306-25. http://dx.doi.org/10.1128/CMR.18.2.306-325.2005
6. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo JD, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo β-lactamase and its plasmidand integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother. 2000;44:891-7. http://dx.doi.org/10.1128/AAC.44.4.891-897.2000
7. Riccio ML, Pallecchi L, Fontana R, Rossolini GM. In70 of plasmid pAX22, a blaVIM-1-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob Agents Chemother. 2001;45:1249-53. http://dx.doi.org/10.1128/AAC.45.4.1249-1253.2001
8. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004;48:4606-10. http://dx.doi.org/10.1128/AAC.48.12.4606-4610.2004
9. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitliks SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998;244:379-86. http://dx.doi.org/10.1046/j.1365-2796.1998.00379.x
10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81. http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x
11. Gutiérrez O, Juan C, Cercenado E, Navarro F, Bouza E, Coll P, et al. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother. 2007;51:4329-35. http://dx.doi.org/10.1128/AAC.00810-07
12. Rossolini GM, Luzzaro F, Migliavacca R, Mugnaioli C, Pini B, De Luca F, et al. First countrywide survey of acquired metallo-β-lactamase in gram-negative pathogens in Italy. Antimicrob Agents Chemother. 2008;52:4023-9. http://dx.doi.org/10.1128/AAC.00707-08
13. Juan C, Beceiro A, Gutiérrez O, Alberti S, Garau M, Pérez JL, et al. Characterization of the new metallo-β-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. Antimicrob Agents Chemother. 2008;52:3589-96. http://dx.doi.org/10.1128/AAC.00465-08
14. Peña C, Suárez C, Tubau F, Gutiérrez O, Domínguez A, Oliver A, et al. Nosocomial spread of Pseudomonas aeruginosa producing the metallo-β-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. Clin Microbiol Infect. 2007;13:1026-9. http://dx.doi.org/10.1111/j.1469-0691.2007.01784.x
15. Riera E, Cabot G, Mulet X, García-Castillo M, Del Campo R, Juan C, et al. Pseudomonas aeruginosa carbapenem resistance mechanism in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother. 2011;66:2022-7. http://dx.doi.org/10.1093/jac/dkr232
16. Viedma E, Juan C, Acosta J, Zamorano L, Otero JR, Sanz F, et al. Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. Antimicrob Agents Chemother. 2009;53:4930-3. http://dx.doi.org/10.1128/AAC.00900-09
17. Cantón R, Perez-Vazquez M, Oliver A, Sanchez Del Saz B, Gutiérrez MO, Martinez-Ferrer M, et al. Evaluation of the Wider system, a new computer-assisted image-processing device for bacterial identification and susceptibility testing. J Clin Microbiol. 2000;38:1339-46.
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, vol. 26, no. 3. 16th informational supplement. M100-S16. Wayne (PA): The Institute; 2006.
19. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233-9.
20. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J Clin Microbiol. 2004;42:5644-9. http://dx.doi.org/10.1128/JCM.42.12.5644-5649.2004
21. Pournaras S, Maniati M, Petinaki E, Tzouvelekis LS, Tsakris A, Legakis NJ, et al. Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4. J Antimicrob Chemother. 2003;51:1409-14. http://dx.doi.org/10.1093/jac/dkg239
22. Gibb AP, Tribuddharat C, Moore RA, Louie TJ, Krulicki W, Livermore DM, et al. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7). Antimicrob Agents Chemother. 2002;46:255-8. http://dx.doi.org/10.1128/AAC.46.1.255-258.2002
23. Crespo MP, Woodford N, Sinclair A, Kaufmann ME, Turton J, Glover J, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol. 2004;42:5094-101. http://dx.doi.org/10.1128/JCM.42.11.5094-5101.2004
24. Ryoo NH, Lee K, Lim JB, Lee YH, Bae IK, Jeong SH. Outbreak by meropenem-resistant Pseudomonas aeruginosa producing IMP-6 metallo-beta-lactamase in a Korean hospital. Diagn Microbiol Infect Dis. 2009;63:115-7. http://dx.doi.org/10.1016/j.diagmicro-bio.2008.08.019
25. Deplano A, Rodriguez-Villalobos H, Glupczynski Y, Bogaerts P, Allemeersch D, Grimmelprez A, et al. Emergence and dissemination of multidrug resistant clones of Pseudomonas aeruginosa producing VIM-2 metallo-beta-lactamase in Belgium. Euro Surveill. 2007;12:E070118.2.
26. Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother. 2005;49:3538-40. http://dx.doi.org/10.1128/AAC.49.8.3538-3540.2005
27. Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN. Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-betalactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). Antimicrob Agents Chemother. 2009;53:1225-7. http://dx.doi.org/10.1128/AAC.01011-08
28. García-Castillo M, Del Campo R, Morosini MI, Riera E, Cabot G, Willems R, et al. Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals. J Clin Microbiol. 2011;49:2905-10. http://dx.doi.org/10.1128/JCM.00753-11
29. Cholley P, Thouverez M, Hocquet D, van der Mee-Marquet N, Talon D, Bertrand X. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. J Clin Microbiol. 2011;49:2578-83. http://dx.doi.org/10.1128/JCM.00102-11
30. Nemec A, Krizova L, Maixnerova M, Musilek M. Multidrug-resistant epidemic clones among bloodstream isolates of Pseudomonas aeruginosa in the Czech Republic. Res Microbiol. 2010;161:234-42. http://dx.doi.org/10.1016/j.resmic.2010.02.002
31. Libisch B, Balogh B, Füzi M. Identification of two multidrug-resistant Pseudomonas aeruginosa clonal lineages with a countrywide distribution in Hungary. Curr Microbiol. 2009;58:111-6. http://dx.doi.org/10.1007/s00284-008-9285-7
32. Elias J, Schoen C, Heinze G, Valenza G, Gerhaz E, Riedmiller H, et al. Nosocomial outbreak of VIM-2 metallo-β-lactamase producing Pseudomonas aeruginosa associated with retrograde urography. Clin Microbiol Infect. 2010;16:1494-500. http://dx.doi.org/10.1111/j.1469-0691.2010.03146.x
33. Pagani L, Colinon C, Migliavacca R, Labonia M, Docquier JD, Nucleo E, et al. Nosocomial outbreak caused by multidrug-resistant Pseudomonas aeruginosa producing IMP-13 metallo-beta-lactamase. J Clin Microbiol. 2005;43:3824-8. http://dx.doi.org/10.1128/JCM.43.8.3824-3828.2005
34. Duljasz W, Gniadkowski M, Sitter S, Wojna A, Jebelean C. First organisms with acquired metallo-beta-lactamases (IMP-13, IMP22, and VIM-2) reported in Austria. Antimicrob Agents Chemother. 2009;53:2221-2. http://dx.doi.org/10.1128/AAC.01573-08
35. Acosta J, Merino L, Viedma E, Poza M, Sanz F, Otero JR, et al. Multidrug-resistant Acinetobacter baumannii harboring OXA-24 carbapenemase, Spain. Emerg Infect Dis. 2011;17:1064-7. http://dx.doi.org/10.3201/eid1706.091866
36. Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008;46:862-7. http://dx.doi.org/10.1086/528712
37. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 22nd informational supplement. M100-S22. Wayne (PA): The Institute; 2012.